Actinium Pharmaceuticals announced data presented at Society of Immunotherapy of Cancer Annual Meeting further supporting Actimab-A, the company’s clinical stage targeted radiotherapeutic comprised of the CD33 targeting antibody lintuzumab and the Actinium-225 alpha-particle emitting payload. The poster highlighted Actimab-A’s ability to target and deplete myeloid-derived suppressor cells – MDSCs -, which uniformly express CD33. MDSCs are a cell population of interest as they remodel the tumor environment and promote immune evasion. Actinium believes Actimab-A has the potential to be used in combination with immunotherapy, including immune checkpoint inhibitors, to enhance antitumor immunity via targeted MDSC depletion.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATNM:
- Actinium Pharmaceuticals names Lynn Bodarky as Chief Business Officer
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- H.C. Wainwright sees Actinium Pharmaceuticals as prime candidate for acquisition
- Eli Lilly deal for Point puts radiopharma names in spotlight
- Point Biopharma deal reads positively to radiopharma names, says B. Riley
